Replay available

HUTCHMED (China) (HKEX:13) Q2 2022 Earnings Call

HUTCHMED (China) (HKEX:13) Q2 2022 earnings call, held 2022-08-02. Watch the replay and read the transcript on 6ix.

Tue, August 2, 2022 at 8:00 AMendedReplay
HUTCHMED (China) (HKEX:13) Q2 2022 Earnings Call
Company
HUTCHMED (China) Limited (HKEX:13)
Period
Q2 2022 earnings call
Date
Tue, Aug 2, 2022, 8:00 AM ET
Replay
Watch the replay on this page · 1 h 10 min

On 6ix: 6ix.com/event/hutchmed-china-limited-hcm-q2-2022-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Dr. Merrick Kanye, our Managed Director and Chief Medical Officer of HutchMed International, Dr. Karen Atkin, our Chief Operating Officer, and Mr. Hong Chen, our Chief Commercial Officer of China. So with that, I will hand over to Dr. Su.

0:21 Thanks, Mark.

0:23 Hello, everyone. As you all know, the biotech industry is going through some significant changes. HutchMED is trying to stay focused on our goals and objectives. During the first half of 2022, HutchMED China Commercial continued to grow and deliver strong results, particularly fulfilling considering the impact from the COVID disruptions. Ellunate continues to gain in prescription share for third-line CRC. The lead over Stavaga continued to widen. Celenda was included into the NRDL this year with a 52% price reduction, yet sales grew 69% aided by much improved patient access.

1:24 All pathos also deliver strong sequential growth compared to second half 2021. On the pipeline, while we were disappointed by this zero fat in the US FDA CRL and now MAA withdrawal, our deep and broad pipeline continues to progress. Our first multinational MRCT for frequentinib global registration will read out shortly in August. And if positive, NDA filings will begin towards end of the year, starting from the US, followed by EU and Japan.

2:12 For savalitinib, multiple registration studies, including global MRCT SAMETA for PRCC and CEFRON, for non-small cell lung cancer are enrolling. The SAVANNAH study, data to be disclosed at WCLC shortly, is also continuing to enroll with potential for filing for accelerated approval. Registration studies for our second wave of products, Emdesilicib, Solve the Planet, and Tesmetastat are all enrolling. and NDA submissions in China are expected during 23 and 24.

2:59 Finally, managing changes and challenges. HutchMED has gone through many difficult stretches in our history. The management team is very experienced in dealing with challenges such as our zero fattening setback or the COVID disruption in China or the overall and many more. Next, I'll ask Mr. Hong Chen, Chief Commercial Officer of China, to give an update on first half China oncology commercial performance. Chen Hong.

3:54 Thank you, Weiguo. Hello, everyone. HutchMED already has three in-house innovative products approved and marketed in China, and 2022 is also the second year for HutchMED to commercialize analytics and Solenda through its own commercialization platform. From this slide, we can see After successful NRDL renewal with only 5% price decrease, Annuit continued to grow strongly first half of this year. The first six months in market sales was more than 50 million US dollars with 26% growth versus last year.

4:45 By the end of May, the cumulative in-market sales cells of Annulate already achieved more than 1 billion RMB. Annulate already benefited more than 50,000 CRC patients. And it continued to expand the leading position in third-line CRC patient share to 43% during the latest post-launch survey. Next slide, please. For Solenda, the NRDA inclusion allows much wider patient access for Solenda.

5:30 We can see despite a 52% price cut, the value sales still increased by 69% to 13.6 million in the first half of this year, which was already over the whole year sales of 2021. The growth was up to 280% in terms of the new patient numbers treated by Selina. Next slide, please. This is the first year anniversary for Sovanitinib since it's approved in June last year. The first half of this year in market sales increased by 46% to $23.3 million.

6:22 versus the second half of last year. As the first in-class selective MET inhibitor in China, savanitinib is now recommended for treatment of non-small cell lung cancer with exon 14 skipping in five Chinese treatment guidelines. And MET diagnostic testing is already recommended as the new standard of care for patient with late stage Long-Support Sales and Cancer. Our commercial partner AstraZeneca is now proactively working on the preparation for the coming NRDL negotiation at the end of this year. Next slide, please.

7:11 This slide is high-level summary of HutchMed commercial capabilities. We can see with the team size increasing to more than 800 staff More and more hospitals and HCPs can be covered as well. More than 500 new hospitals were covered in the first half of this year, especially in Tier 2 and Tier 3 CPs. More and highly effective promotion events executed in first half, especially through online and digital communication to mitigate the COVID For example, we can see we held more than 3,800 annual events with more than 100% growth versus the first half of last year. And we covered more than 43,000 HCPs by Solenda events with also more than 180% growth.

8:23 So overall, in despite of the COVID challenges, we continue to make good progress to commercialize our three market products in China in the first half of this year. I'm very confident this momentum to continue to go from strength to strength as our commercial team continues to build over the balance of this year. Thanks. Okay, Weiguo and Merrick, please.

8:55 Thanks, Cheng Hong. Moving on to the pipeline progress. Our clinical development pipeline continued to grow. Our anti-CD47 antibody, HMPL-883, entered into Phase 1 study. And our first in-license product, Tazometastat, initiated the bridging study for China registration. Next slide. This slide lists 13 ongoing registration studies, both China and globally, with estimated timeline for possible NDA filings. Generally speaking, the COVID outbreak in the first half has some impact on enrollment, and we are anticipating some delay for most studies in China.

9:53 Next slide. Again, the seven registration studies for Savaletinib, and they are all enrolling, three globally and four in China. Next slide. This is to highlight the interim Savannah data to be presented at the WCLC. The most important information, among other things, is the biomarker definition. The data is from 193 patients, all progressed on Tabresa with MET activation, both high and moderately high. In this study, 34% of patients were identified with high MET activation, namely IHC3+, greater than 90% of the tumor cells, or MET gene copy number, An additional 28% with moderate med activation, IHC3 plus less than 90%, or GCN between 5 and 10 copies.

11:07 As you can see, there is a clear difference in efficacy for these two subgroups of patients, including OLR, DLR, and PFS. supported and informed the Global Cephron Registration Study, which is now underway. Next slide. In addition to targeting MET driver genetic alterations, such as mutations, exon 14 skipping, or amplification, another area of strong interest is to target the immunosuppressive role of HGF Met Signaling Pathway. Last year, we published the Calypso study in which the met-driven PRCC patients appeared to derive robust clinical benefit from the treatment of sevalitinib to valumab combination.

12:08 Currently, the global registration MRCT is ongoing, the SAMETA study. We and our partner, AstraZeneca, are now preparing to explore the same combination in med-driven non-small cell lung cancer. The Sun study is expected to start enroll later this year. Next slide. Moving on to frequentinib and through fatinib clinical development outside China, let me ask my colleague, Dr. Merrick Kenia, managing director and CMO of HMI, to give you an update.

12:48 Thank you, Weiguo. Hello, everyone. I will give you a quick update on our late phase development globally. As you can see on this slide, HutchMed continues to focus on colorectal cancer and really helping patients with this high burden and high unmet medical needs to find solutions. And therefore, frequenting it was our main focus in driving that help, as you can see. This is the second most common cancer type. And post-second line standard therapy patients are running quickly out of options. Only two approved options in the third class line is used in the less than 20% of total patients.

13:36 So that highlights strong needs and strong rationale for frequency being developed in this setting. Next slide, please. As you've seen this slide, The last six months was our strong focus of driving our FRESCO II, which is second physical study, multinational MRCP to go through the finish line. We are actually narrowing our predictions here. We will be in position of sharing top-line results in August. and presenting at upcoming medical conference for results very soon.

14:22 Just as a reminder, FRESCO 2 was discussed with all major regulatory agencies before finalizing protocol and start of the contact. Therefore, if FRESCO 2 is positive, it will be key base for regulatory efforts both in US for NDA Europe, MAA, and Japan PMDA discussion. Japan has strong participation in this study, so through this truly global effort, it will be our strong position from a regulatory point of view to start our mission. As a reminder, U.S. grant, U.S. FDA granted fast track designation Therefore, it will afford us rolling submission starting in late this year if Fresco feels positive.

15:15 Again, I will be talking more about Fresco 2 very soon. Next slide, please. So if I can give a quick update, we had discussions earlier in April, May about NDA countries response in US. I'm not going to highlight more of this. Today we announced withdrawal of our MAA in Europe. Main reasons are summarized in this slide, which really highlights similar concerns and similar limitations on objections from European regulatory perspective. In addition to this limitations in conducting inspections both GCP and GNP led to our discussion and decision to withdraw and focusing on path forward with both regulatory agencies to bring super fattening to next stage development conducting MRCC.

16:23 For Japan, we are conducting a bridging study or different name for this would be pivotal study in Japanese regulatory term And we are in part two. We will be approaching PMDA for pre-MDA discussions at the conclusion of that study. Next slide, please. Weiguo, I think you will be covering this slide.

16:49 Thanks, Eric. Now let's move on to our second wave of compounds in late-stage development, all in the heme-onc space. HutchMED has six assets in clinical development with several more programs in discovery. We believe this is a highly valuable Hiemang pipeline covering pretty much entire Hiemang spectrum. And M does elicit Solve the Planet, both with breakthrough therapy designation in China. Next slide. M. desalicyp, our differentiated Tiafrica Delta inhibitor with good safety profile, has continued to enroll in two registration phase two studies, the third line plus follicular and the second line or above marginal zone lymphoma.

17:52 Data for other subtypes of lymphoma including MCL and PTCL are still maturing. and will be evaluated for possible additional registration studies. Outside China, in light of the April FDA ODAC on PR3K-Delta class of compounds, we are expanding patient enrollment in several subtypes to demonstrate or confirm the differentiation with a priority in post-BTK IMCL and PTCL. Let me remind you that our intention when MDIS ELISIB was discovered was to improve upon existing piastric delta inhibitor safety profile, which is now the center of the question.

18:44 The data we published at ASH last year showed not only this promising efficacy data, but also a much more favorable safety profile obviously needed to be further confirmed in larger patient population and also in U.S. patient population. In addition, also considering combinations such as the EZH2 inhibitor, Tasmetastat. Next slide. Solve the Planet, the SICK inhibitor. In China, the phase three registration study in ITP is enrolling very well with little impact from COVID, suggesting A strong medical need in this patient population.

19:33 We hope to complete enrollment of this phase three study by end of the year. Behind the ITP, two INDs have been cleared in China, one for autoimmune hemolytic anemia and another for COVID-19. to explore its anti-inflammatory activity to reduce death rate in severe to critical patient population. Outside China, the dose expansion in lymphoma indications continues to enroll with a priority in Hodgkin's and post-BTK CLL, in addition Based on the encouraging POC data from the China ITP study and strong on-map medical needs in this space, we are preparing to submit an R&D to explore the potential.

20:35 Next slide.

20:38 Our in-licensed EZH2 inhibitor test metastat test is approved in the US for follicular and epithelial Epithelioid sarcoma indications as a monotherapy at 2022 ASCO, the safety run-in data in combination with R-square was presented in a second-line follicular lymphoma. The efficacy and safety were very encouraging. Together with our partner Epizyme, the global phase 3 study, the Symphony-01, has been initiated in second-line follicular comparing R-square plus test versus R Square. China will be part of the global MRCT to support China registration.

21:29 In parallel, we just kicked off the bridging study in China to support initial registration of Tazmetastat as a monotherapy. Taz has been approved in Hainan Province in China through a special registration pathway based on the U.S. approval. Multiple combination proof of concept studies are also being planned. So this update on the late stage assets. Next, I'll ask Johnny Chan, CFO, to give us an update on the financials. Johnny?

22:13 Thank you, Weiguo. So moving on to the next page, please. So as of June, the company maintains a strong balance sheet. We have cash and short-term investments of over $800 million, and utilized banking facilities of over $170 million. In addition, we have another $58 million cash in our joint venture with Shanghai Farm. So overall, our target is to extend the cash run rate to three years. Move on to the next page. The strong performance of our commercial teams resulting group revenue up by 28% to over $200 million, of which our oncology business revenue increased by more than double of last year to more than over $90 million.

23:01 So we continue to increase our investment in R&D to over $180 million in China as well as in U.S. and Europe. So the probability of our equity investors increased by 17% to over 33 million. Moving on to the next page, please. Our non-core assets continue to do well. So as you all can see, it has contributed more than half a billion net income to the group. So we continue to explore ways to unlock the value of these assets. to provide additional cash resources to support our R&D investment. Moving on to the next page. As you all have heard from Hung Cheng earlier, with our strong performance, commercial performance, we will maintain our guidance to the market we gave earlier. That is 160 to 190 million for our oncology and immunology business. I will now pass on to Weiguo.

24:05 Okay, thanks, Johnny. To recap, while the macro environment continues to change, HutchMED strives to stay focused on our commercial operations and pipeline progression. We expect that the strong momentum in China commercial to continue in the second half. On the pipeline, in China, we continue to expand the lifecycle indications behind our three approved products, fruquinitinib, sirufatinib, and savalitinib. And at the same time, moving our second wave of drug candidates, amdesalicitib, sovliplanib, and tesametastat towards registration.

24:52 Outside China, while sirufatinib has been a disappointment, we believe it is a unique case and won't have and a significant impact on the rest of the pipeline. And we do have a deep pipeline and a robust registration strategy, starting from through Quintinet, for which a multinational MRCT will read out shortly in August, and NDA filings, if positive, in the US, EU and Japan, starting from the end of the year. MDIS ELISIP and Solve the Planet are both generating POC data and will be engaged with the FDA to discuss and define the registration pathway in the next six to 12 months.

25:42 Finally, I would like to point out that even though we have a solid cash balance, we are prepared to manage through potentially long-lasting unfavorable equity market. We are reviewing our clinical programs, and operations carefully to make sure that we spend cash prudently. We will also look to grow our China business further to generate more income. And finally, we plan to up our efforts in licensing and collaboration activities. Our current environment is challenged. We are confident that we will be able to leverage our wealth Experience management team and emerge from the difficult period even stronger.

26:36 This is not the first time that we have managers through difficult market conditions. So this wraps up our presentation. The management team will be happy to answer any questions. Ladies and gentlemen, we will now start our question and answer session. If you wish to ask a question by phone, please press 01 on your telephone keypad to enter the queue for the question and answer session. To cancel the queue, please press 02. We have some questions coming and the first one comes from Kelly Chi from Jefferies. Please go ahead.

27:23 Congratulations on the progress and thank you for taking my questions. So regarding the regulatory pathway for Quintinib in the U.S. based on a global Phase III FRASCO trial, a U.S. Phase I trial, and a FRASCO China trial, which should provide comprehensive clinical information, but given the experience with Suru, do you see any potential issues regarding the applicability to the U.S. patient population and also to the current U.S. medical practice of the Thank you, and also have a follow-up. Okay, thanks, Kelly. Well, obviously, you know, the strategy for frequenting registration in the U.S.

28:23 and elsewhere for that matter obviously will be centered on the FRESCO II study which is obviously MRCT and in representative patient population. I think the China study, the original FRESCO study and also all other early stage clinical studies will serve as supports. So we don't expect any issues and we certainly had previous discussion with the agency as well before we actually kicked off the FRESCO II. So we are actually quite confident that this MRCT should cover most issues.

29:09 It's completely different from a pseudo-fattening case. Maybe, Merrick, if you want, you have anything else to add?

29:20 Yeah, Weiguo, thank you. You know, I would just add my voice of confidence, you know, and as you said, well, first of all, for Quentin's case, it has nothing to do with Suva Fata's case, which is unique. We had numerous formal discussions with the US FDA in the end of Phase II meetings, Type C meetings. and we were very transparent and FDA was very collaborative in the way how we designed this Fresco 2 study, which is main pivotal study. Fresco 2 will be considered in totality of the package as well. So we are very confident if Fresco 2 is positive, that would be based on three continental regulatory discussions.

30:13 We already reported before, we had also scientific advice with IMA, which provided comments to Fresco II design. For Europe, Fresco II will be a primary pivotal study. At the same time, we had the same discussion with PMDA, so we remain very confident in our strategy here.

30:41 Gui Tu here. Thank you very much. I also have a follow-up regarding the PS3 kinase inhibitor. And how should we think about the market opportunity in the lymphoma indications in China market given CD19 CAR-Ts and also CD20 bispecific antibodies have entered the market and there are also a few entering the market. How different of the competitive landscape in China versus in the U.S. for those lymphoma indications. Thanks.

31:17 Yeah. So, you know, obviously, it all comes down to the safety and tolerability. If proven safe and efficacious, we believe Piafria Delta should have, you know, a very Thank you very much. Thank you. has shown some strong data.

32:12 But again, these are all single arm studies and still remain to be confirmed. CAR T's can work for some patients, but not for all. And even patients benefit, they ultimately progress or have recurrence. So all in all, we believe In the lymphoma patient population, it's a big population, and patients live for a long time, and they need to rotate to new therapies repeatedly. So a good, efficacious, and safe, tolerable piastric delta inhibitor we believe has its place for these patients.

33:02 Very helpful. Thank you.

33:06 Thanks. Do you hear anything? Operator?

33:55 Hello, Paul Choi from Goldman Sachs. Your microphone is open.

34:01 Thank you. Good evening and thank you for taking our questions. Just a couple of quick financial ones to start and then one pipeline question. First, was there any inventory billed at the end with regard to some of the newer products that were included on the NRDL? And then with respect to the guidance being maintained, can you maybe speak to how you view the current macro environment and what would be the pushes and pulls that might drive your full year results to the lower end versus the higher end? And then I had a pipeline question to follow up.

34:38 Yes, Paul. With regard to the inventory, we believe at the moment it's a normal inventory. Thank you very much. With regard to the push and pull, again, I think we are a bit concerned about the COVID-19, whether it can now have another outbreak somewhere else or somewhere.

35:35 And it can be quite disruptive, basically. So that remains a bit uncertain. Nobody can predict the situation. Although we have gone through once and Chen Hung's team is putting in place multiple measures, including the online doctor's visit, online conferences, and also the inventory and distribution management. We believe we are now better positioned to deal with any potential COVID outbreak in China or lockdowns potential. But nevertheless, it can be an issue, depending on the scale, obviously.

36:25 So we are cautiously optimistic that we'll be able to deliver within the guidelines, and hopefully we can do better towards the higher end. So I think the only pull or the headwind would be the uncertainty of COVID.

36:52 Okay. Thank you for that. And as a follow-up, my pipeline question is, I know you'll have the FRESCO II results imminently here in August. Is there a plan to present the data more in detail at a medical meeting here in the second half of 22? Or will we have to wait until 2023? Thank you for taking our questions.

37:13 Yeah, I can take it. So Paul, obviously our principle is disclosure of important data, both in an announcement level expeditiously, but also in a full data set as quickly as possible at the major conference. So I'm not here in a position to confirm which conference. You can go and speculate, but our aim is always We have another question from Mike Mitchell from Palmyra Garden. Please go ahead.

38:11 Thanks. Good afternoon, everyone. Many thanks for taking my questions. I just have a couple. I just wondered in terms of the current commercial organization, you know, you're continuing to add significantly to the oncology team. I think you stated you're over 800 people now. But the number of oncology physicians covered is starting to flatten off somewhat. So I just wondered how optimal the commercial organization now looks just in terms of structure. And then a question on fruquinitinib and the sort of global strategy. Clearly the first two data is important in terms of paving the way towards the regulatory process outside of China and more widely also for the global strategy for the business. But if that doesn't play out as we hope, then I think you're probably then looking at the global savalitinib studies, Samita and Saffron, to progress the global story, which are a little way out in terms of potential NDAs.

39:02 I just wondered if you could recap the Tasveric Global Plans in that context, please. Thanks.

39:10 Okay, thanks, Michael. With regard to the commercial organization in China, we are now around 800 staff. We believe this is the optimal scale for the current portfolio of products. So we don't grow further. However, instead we'll focus on driving efficiency and driving productivity from the current staff. With regard to your second question on the frequentium global registration, I think it There can be all kind of scenarios, but first things first, we need to wait until the FRESCO 2 data to read out.

40:07 And personally, I'm, you know, just like you all, anxiously waiting for the FRESCO 2 to read out. And I think through Quinti we have accumulated a wealth, you know, I don't know if, Marek, you have anything else to add?

40:38 You said it well. Obviously, given proximity of the outcome, obviously, we are thinking, like all of you, about positive, negative outcome. But given the wealth of data, including one positive study, in addition to a number of other studies, Our cohorts from the U.S. studying across different lines of prior lines of therapy with the consistent of results and clinical benefits demonstrated. There's nothing to make us, you know, concerned about anticipation, but we are doing studies for a reason. And in the normal circumstance, you know, if you do the first pivotal study, you have approximately 17% probability of success in any study, given our already one positive study, we are confident. But again, let's finish this cross, let's cross this finish line. And we are planning for success for now, but we will adjust accordingly if in any case negative outcome, I'm surprised.

41:46 Science is science. Okay, that's very.

41:55 And I think the next one was related to like of post-Sav or global, maybe that angle of question. Do you want to address?

42:07 Well, obviously, you know, post the FDA CRL and also considering their recommendation of MRCT. Are you talking about surafatinib?

42:20 No, Sam, no, no. I think the question was in case of negative frequentinib, will our focus shift entirely to sublatinib global development from that perspective? I mean, both programs are important, correct?

42:37 I think, no, obviously, if negative, it will be a major setback, right? I mean, it It's just similar to serifatinib in the CLL. Obviously, we remain confident that these are valuable drugs that can help patients, but the setback basically is a timeline. It's going to push back significantly years. We're talking about three, four years for the first So, you know, we are, you know, we'll be, you know, evaluate very carefully, similar to what we, what we are doing for Srufetinib, and we'll be doing the same for Fuquentinib if negative.

43:33 Again, you know, the NPVs can change greatly if, you know, If the timeline continues to be pushed back. So that's an area we need to be very careful.

43:47 Understood. That's right, guys. Thank you. Next question comes from Zhang Hong from Credit Suisse. Please go ahead. Yes, this is Yang from Credit Suisse. Thanks for the opportunity for me to ask a question. The first one, actually, I just want to have a follow-up on FRASCO2. I know some of my peers already asked about this study. I think given the study, actually, trial started in, I think, second half 2020. However, we all know FDA certainly changed their position into reviewing drugs from China in 2021. So it will be very helpful if we can get some more colors about what kind of communication we had before we started the FRESCO2 study with FTA.

44:53 So what we talk about with FTA before we started the FRESCO2 trial, Have the company noticed any kind of potential change in FDA's view after 2021 events? Thanks. I have a follow-up on financial too.

45:16 Yeah, I think we already touched on this. Now, obviously, we had end of phase two or pre-phase three discussion with the U.S. FDA, and it got aligned. on the study designed for FRESCO 2. And if positive, obviously, we'll have another opportunity for a pre-MDA discussion likely. And also note that this particular indication, we have fast-track destination, and we can discuss it with the agency at any time. With regard to FDA kind of position, I'll ask maybe Merrick to chime in. He obviously has more involvement in the discussions with the FDA.

46:21 Eric?

46:22 Yeah, so thank you, Ryan. Just to clarify, I simply hear some confusion in the system here. You know, overall challenges with surfactant and any other sponsors related in this situation was related to agency concern where Application to NDA is made with one country phase three trial or phase three trials. That's the core of their concern. Bringing one country and this China, no China, it's just even broader. If you would bring to one country specific, not necessarily applicable to US populations. That's the core of their concern. The first go-to is a very different case of frequenting. It is a very different case.

47:14 As Weiguo said, we had pre-NDA, end of phase one meeting or pre-phase three meeting. We had another type B, very similar meeting this year. And we are preparing for type C meeting very shortly post-topline results. So, so far, agency has been very consistent and therefore, Again, important fact is we are running global study, global study conducted in 14 countries, 160 sites, and US is contributing to this study in a significant way. So it cannot be more than multinational, more than regional study. It is exactly what agency is expecting.

48:01 Every other study supporting or part of the package will play important role as well. So yeah, don't overplay that. Overall, you know, concerns were still happening into everything else moving forward because it's not the thing. Thank you, Wai-Jing. Okay, got it. Yes, thank you. And my second question is on our financials. So we noticed in the first half our total revenue has a pretty good growth, I think, Thank you for the question. I'll ask Johnny to

49:06 to provide the answer.

49:12 Okay, thank you, Weiguo. I think it's the composition of our products. If you compare to the last period, we did not have subalternate in the first half, which we now have subalternate in our first half of this year. As you all know, we recognize for subalternate in-market sales We actually recognize 30% of the royalty. So that actually improves in terms of our gross profit margin. And on the other hand, of course, we have invested into our sales force, which are part of which we capture in the course of sales. So combining all together, the product mix actually makes a difference to the analysis that you just referred to. But going forward, I think we will continue, hopefully, I think we are targeting to continue to do well in LNA and serotonin. At the same time, I think the proportion of serotonin sales should increase over time.

50:21 I hope that answers your question. Okay. That's very helpful. Thanks. Next question comes from Luis Chan from Cantor. Please go ahead.

50:37 Hi, this is Wayne Arnfor-Lewis, and thank you for taking our questions. So our question is on serofetinib. The EMA indicates that these studies were not representative of patients and medical practice in EU. So why do you think this wouldn't be a potential complication in Japan? And just to clarify, will you still pursue global path forward to serofetinib in light of the US and EU need for local trials? Thank you.

51:05 Well, I think, you know, it's understandable that that particular argument is almost identical from U.S. CLL, which is the patient, you know, representative patient population. I think in Japan, it is quite different. First off, obviously, they are Asians, right? And secondly, it's on a different registration path. They requested us to do a bridging study. So that study is ongoing. And obviously, we'll continue to discuss with the DMDA in Japan. And clearly, I think it's understandable between Asian and Caucasians in terms of patient population difference.

51:55 Japan, they are Asians, but they also on a very different Registration Files. Anything else to add, Marek?

52:12 No, I would only add or highlight. We called Silphatin's kind of case as a unique case, and actually Japan's case will be as unique as it can be. I don't recall personally two Phase III studies coming from Weiguo said with bridging study phase one will engage post-conduct of this study which we expect in 2023 and discuss you know path forward in the pre-NDA discussion so We'll see. As you know, Japan always also look at NDA's approval in the U.S., so there may be some bias persistent in that context.

53:13 But we'll cross the bridge when we have the data.

53:19 Got it. Thank you. Next question comes from Matthew Yang from CLSA. Please go ahead.

53:32 Hi, management. Thanks for taking my question and congratulate on the result. I got two questions regarding the validity. First is that I noticed on your presentation material, you mentioned that you filed the NDA based on SEPRON in 2025. Does this mean that the SAVANA data will not support an NDA filing in the near term? And my second question is regarding SAVANA readout. It was just published. How will you see this help differentiates in terms of its clinical profile versus peers that are already approved, like tapotinib and comatinib? Those are two of my questions. Thanks.

54:20 OK, thanks. Thanks, Matthew. Well, the CEFRON NDA timeline 2025 is obviously an estimate. I think we just got it started. So it all depends on the enrollment speed and also the PFS follow-up, which sometimes it can be longer than what we expect. But the Savannah, I think we probably have

54:51 and more clarity, right? So obviously we need to get aligned with the US FDA on the potential to, you know, for sabalitinib Savannah study to support an accelerated approval. But we think, you know, both Hutchimed and AstraZeneca, our assessment is that Savannah can be At least the approval timeline can be 12 to 18 months ahead of CEFRON in the U.S. Now your second question on the regarding the differentiation with the tepotinib and others. Now I think Obviously, we have not, you know, these two compounds, Tiponimed and Capimed, they're not approved in China yet. They've been exposed to very limited number of Chinese patients.

56:02 Just looking at the profile, I think, you know, they're all potent and selective C-MED inhibitors. However, they vary significantly in terms of chemical structures. So I would expect differences in pharmacokinetics or in compound-based safety profiles. So because they have limited exposure in Chinese patients, it's hard to tell the difference. And you can't compare from the Chinese study versus the department of or chem-medicine studies outside China. With regard to other studies, I think, you know, clearly AstraZeneca has the Ocimolatinib and they know the patients very well.

56:59 Now we have the biomarkers figured out. So we think we are in a pretty good competitive, we have a pretty good competitive edge over the other two products in terms of in the in the EGFR TKI refractory patient population. Else, you know, other studies, I think we are the only, we have the only combination in PRCC, and I think we are also the only, several is the only compound now exploring gastric as well. So I think we have a much broader, you know, I think the challenge with MET is it's very fragmented.

57:53 It has multiple types of driver genetic alterations, including point mutations, exon 14 skipping, amplification, and fusion, and so forth. And they all require different diagnostics to support. just very tedious to do because of low incidence and difficult diagnostics. But we've, at least AstraZeneca and HushMed, we have made good progress in non-small cell lung cancer gastric and PRCC. I'm sure there are other, there are multiple other tumor types such as CRC, for instance, head and neck as well.

59:03 We have another question from Alex Tran Han from Bank of America. Please go ahead. Hey, guys. Good morning. Thanks for taking our question. This is John. I'm on for Alec. Kind of a two-part question from us. So you're on the FRESCO II trial. Through your conversations with the U.S. regulatory agency so far and through your experience, more or less viewing the data, are they going to view it in kind of the grander landscape of the current U.S. budget market? Or are they going to kind of also look into a comparison with the Frisco 1 Chinese trial? So that's the first part.

59:50 And just to build off of that, if they do look into the comparison with the initial Frisco 2 Chinese trial, do you think that they will be factoring in the fact that an MRCT with a harder to treat population in the US and international landscape will potentially be a factor at play? That's my question. Thank you.

1:00:14 Yeah, I think that's a really good question. I think, yeah, I'll have a brief response and then America can chime in. You know, the FRESCO versus FRESCO-2, obviously these are very different studies, right? Different patient population and different prior therapies. So, But they both have merits and they can support each other. I think that's my initial read on this. I think the FRESCO and all other Chinese studies will form the basis to support the FRESCO too, both in terms of efficacy in different patient population in different settings or subsets, with or without prior VEGF or VEGFR treatment, you know, Chinese versus Caucasians.

1:01:16 So I think that they will complement each other basically. So that, you know, maybe America now you can add further your comments on this.

1:01:29 Yeah, it's a good question, but obviously one statement I will make, obviously cross-study comparisons are very risky, obviously not scientific, although everyone is doing this, as you know. Let's go to study is designed to address uniquely and independently questions designed and built in the standard studies, highly powered, 90% power to detect primary endpoints. Obviously, if positive, this study could stand alone with PRESCO or without PRESCO. But in topality, we always look at the topality of the data. So far, we haven't seen any so-called big discrepancies in prior lines of therapy.

1:02:20 As I mentioned before, we conducted a number of And we see consistency in clinical benefits. So, I mean, I'm not going to speculate here, but FDA, if you're asking me for more precise answer here, We had those discussions and studied design for Fresco 2. It's a pivotal study. It's positive. It will do the job. Obviously, it will use the quality of the data to put the most convincing package. And that's the reason why most clinical investigators and really thought leaders in the field Thank you.

1:03:20 Thank you for calling. It was our last question, so ladies and gentlemen, dear speakers, I give you back the floor for the written questions. Hi, it's Mark. There's some written questions, so I will read them out.

1:04:06 On the online system, we have several questions. The first is, Regarding the Holding Foreign Companies Act, as several companies appointed U.S.-based auditors, does the company have an update on this issue? And regarding this elicit, has the China regulatory authority raised any concerns regarding single arm design? and the management also share the dose selection strategy. Weiguo?

1:04:47 Yeah, at the moment. At the moment, we've had multiple regulatory interactions with China CDE, and the two single-arm studies are ongoing and without modification. So with regard to dose, in the China study, It's a 30 milligram QD flat dose without any dose modifications, basically. I mean, similar, you know, like, as you know, I guess, paraclisib and xanilisib, these compounds modify their dosing regimen throughout the studies, but m-desilisib can be taken, basically, at 30 milligram QG flat and continuous.

1:05:51 Okay, thanks Weiguo. Maybe I can direct this question at Johnny. In the past, or the question is, what is the funding mechanism for the factory? How do we budget the factory?

1:06:10 Thank you, Mark. So for the factory, in terms of the... I'm reading the question also. So the question is how we fund the factory in terms of the total cost of the factory and so forth. We mentioned earlier the total project for the new factory in Shanghai is about $130 million. We have so far spent about $30 odd million. So this year, we target to spend $60 million, but we have a fixed assets The project we target to complete by the end of next year. So, within this year and next year, we will be drawing down, slowly drawing down the required amount for these topics.

1:07:20 Okay, thanks Jonny. Jonny, perhaps I could ask you to answer the question on HSCA as well.

1:07:26 Okay, so, sorry, the question before was related to some of the other companies have changed their auditor, US-based auditor. To our circumstances, it is different to other companies, some of these companies. For us, majority of our operation, assets, revenue generated business are all based in China. So even by changing the auditor to a U.S.-based auditor, we will not meet the requirement as those U.S.-based auditors, they are not qualified to have license to... Thank you, Mark. Okay, thank you, Johnny. Okay, there's another question. Does the takeover of Epizyme by Epstein change anything for development of Tabernetostats?

1:08:42 We don't think so. No, we don't think so. Okay. Okay. I think that's... I think we're running out of time now, so maybe we can draw a line here. Weiguo, do you have any closing remarks?

1:09:05 No, I just want to say we continue to focus on the execution, and we look forward to a good second half, hopefully starting from, I think most important is the fresco, too. Ladies and gentlemen this concludes today's conference call. Thank you all for participating. You may now disconnect.

Follow HUTCHMED (China) Limited into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Wayne Arnfor-Lewis

Analyst

Paul Choi

Analyst, Goldman Sachs

Dr. Merrick Kenia

Managing Director & Chief Medical Officer, HutchMed International

Mike Mitchell

Analyst, Palmyra Garden

Kelly Chi

Analyst, Jefferies

Hong Chen

Chief Commercial Officer, China, HutchMed

Johnny Chan

Chief Financial Officer, HutchMed

Dr. Weiguo Su

President & CEO, HutchMed

Matthew Yang

Analyst, CLSA

More from HUTCHMED (China) Limited